Natixis Investment Managers International Abb Vie Inc. Transaction History

Natixis Investment Managers International

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $14,312 - $18,195	104 Added 0.7%	14,935 $2.29 Million
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $1.96 Million - $2.43 Million	14,831 New	14,831 $2.4 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $1.37 Million - $1.69 Million	-17,593 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $66,504 - $73,932	748 Added 4.44%	17,593 $1.66 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $358,581 - $424,282	-3,994 Reduced 19.17%	16,845 $1.56 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $1.92 Million - $2.57 Million	20,839 New	20,839 $1.97 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $973,606 - $1.07 Million	-10,871 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$69.85 - $89.22 $524,154 - $669,506	-7,504 Reduced 40.84%	10,871 $966,000
Q2 2017 Aug 14, 2017	BUY	N/A	18,375	18,375 $1.33 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

Stay updated on Natixis Investment Managers International with notifications on news.